Comparative effectiveness and cost-effectiveness of cardioprotective glucose-lowering therapies for type 2 diabetes in Brazil: a Bayesian network model
Nogueira A, Barreto J, Moura F, Luchiari B, Abuhab A, Bonilha I, Nadruz W, Gaziano J, Gaziano T, de Carvalho L, Sposito A. Comparative effectiveness and cost-effectiveness of cardioprotective glucose-lowering therapies for type 2 diabetes in Brazil: a Bayesian network model. Health Economics Review 2023, 13: 50. PMID: 37878108, PMCID: PMC10599033, DOI: 10.1186/s13561-023-00466-3.Peer-Reviewed Original ResearchIncremental cost-effectiveness ratioGlucose-lowering therapyType 2 diabetesNetwork meta-analysisSecondary preventionPrevalence of type 2 diabetesBrazilian public health systemRisk of cardiovascular outcomesPublic health systemCost-effectiveReduced relative riskNon-fatal cardiovascular eventsContext of primary preventionConclusionsIn BrazilClasses of glucose-lowering therapiesHealth systemManagement of T2DMGLP-1aCost-effectiveness modelStandard carePrimary preventionCost-effectiveness ratioRelative riskEvidence-basedInternational dollarsAssessment of Atherothrombotic Risk in Patients With Type 2 Diabetes Mellitus
Berg D, Moura F, Bellavia A, Scirica B, Wiviott S, Bhatt D, Raz I, Bohula E, Giugliano R, Park J, Feinberg M, Braunwald E, Morrow D, Sabatine M. Assessment of Atherothrombotic Risk in Patients With Type 2 Diabetes Mellitus. Journal Of The American College Of Cardiology 2023, 81: 2391-2402. PMID: 37344040, PMCID: PMC11466046, DOI: 10.1016/j.jacc.2023.04.031.Peer-Reviewed Original ResearchConceptsType 2 diabetes mellitusSecondary preventionIschemic strokePredictor of MIValidation cohortClinical decision-makingRates of MIMyocardial infarctionAtherothrombotic eventsRisk quintileRisk of atherothrombotic eventsRisk modelSelection of pharmacotherapyRisk scoreAssessed clinical variablesMultivariate Cox regressionClinical trial cohortPooled cohortCandidate variablesCox regressionIS ratesDECLARE-TIMIAbsolute reductionTrial cohortCohort